Onvansertib
Phase 1 Study to Determine the Safety and Efficacy of Onvansertib, A Novel, Oral, PLK1 Inhibitor in Patients With Proliferative Chronic Myelomonocytic Leukemia (CMML) and Myelodysplastic Syndrome/MPN Overlap Neoplasms Relapsed/Refractory or Intolerant to Available Therapies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 25 patients (estimated)
- Sponsors
- Mayo Clinic
- Collaborators
- National Cancer Institute (NCI)
- Tags
- PLK1 Inhibitor
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2171
- NCT Identifier
- NCT05549661
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.